Skip to main content

Advertisement

Log in

Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

MicroRNA-203 (miR-203), possessing tumor suppressive or promotive activities, has been found to be downregulated or upregulated in different cancer types. The purpose of this study was to investigate whether the increased expression of miR-203 can be used as a noninvasive diagnostic and prognostic biomarker in epithelial ovarian cancer (EOC). Real-time quantitative PCR was performed to detect the expression levels of miR-203 in EOC tissues. The expression levels of miR-203 were significantly higher in EOC tissues compared to adjacent non-cancerous tissues (p < 0.001). High expression of miR-203 was observed in 65.38 % (102/156) of EOC. In addition, high miR-203 expression was found to be closely correlated with advanced FIGO stage (p < 0.001), higher histological grade (p = 0.02), lymph node involvement (p < 0.001), and positive recurrence (p < 0.001). Moreover, high miR-203 expression was correlated with shorter overall survival (p < 0.001) and shorter progression-free survival (p < 0.001) of EOC patients. Furthermore, multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.

    Article  PubMed  CAS  Google Scholar 

  2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 2001;51:15–36.

    Article  PubMed  CAS  Google Scholar 

  3. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V, Cinquini M, Dell’Anna T, Apolone G, Broggini M, D’Incalci M. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008;14:7850–60.

    Article  PubMed  CAS  Google Scholar 

  4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  PubMed  CAS  Google Scholar 

  5. Cho WC. MicroRNAs in cancer-from research to therapy. Biochim Biophys Acta. 2010;1805:209–17.

    PubMed  CAS  Google Scholar 

  6. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107:823–6.

    Article  PubMed  CAS  Google Scholar 

  7. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.

    Article  PubMed  CAS  Google Scholar 

  8. Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319:1785–6.

    Article  PubMed  CAS  Google Scholar 

  9. Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res. 2013;41:64–71.

    Article  PubMed  CAS  Google Scholar 

  10. Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, Lee KW. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer. 2013;23:673–9.

    Article  PubMed  Google Scholar 

  11. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27:1238–44.

    PubMed  CAS  Google Scholar 

  12. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.

    Article  PubMed  CAS  Google Scholar 

  13. Huang Y, Shen XJ, Zou Q, Zhao QL. Biological functions of microRNAs. Bioorg Khim. 2010;36:747–52.

    PubMed  Google Scholar 

  14. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67:129–39.

    Article  PubMed  CAS  Google Scholar 

  15. Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007;21:97–104.

    Article  PubMed  CAS  Google Scholar 

  16. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  PubMed  CAS  Google Scholar 

  17. He JH, Li YM, Li YG, Xie XY, Wang L, Chun SY, Cheng WJ. hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide. Exp Ther Med. 2013;5:1315–21.

    PubMed  CAS  Google Scholar 

  18. Boldrup L, Coates PJ, Wahlgren M, Laurell G, Nylander K. Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins. J Carcinog. 2012;11:18.

    Article  PubMed  CAS  Google Scholar 

  19. Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, Dong JT. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2:782–91.

    Article  PubMed  CAS  Google Scholar 

  20. Shah MS, Schwartz SL, Zhao C, Davidson LA, Zhou B, Lupton JR, Ivanov I, Chapkin RS. Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: effect of a chemo-protective diet. Physiol Genomics. 2011;43:640–54.

    Article  PubMed  CAS  Google Scholar 

  21. Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD. MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer. 2011;11:57.

    Article  PubMed  CAS  Google Scholar 

  22. Zhao S, Yao DS, Chen JY, Ding N. Aberrant expression of miR-20a and miR-203 in cervical cancer. Asian Pac J Cancer Prev. 2013;14:2289–93.

    Article  PubMed  Google Scholar 

  23. Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu D, Huang Y. microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J. 2011;278:786–92.

    Article  PubMed  CAS  Google Scholar 

  24. Viticchiè G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli LG, Knight RA, Candi E, Melino G. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10:1121–31.

    Article  PubMed  Google Scholar 

  25. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:3120–8.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wei Xiang.

Additional information

Shaosheng Wang and Xiaohong Zhao have contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, S., Zhao, X., Wang, J. et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol 30, 681 (2013). https://doi.org/10.1007/s12032-013-0681-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0681-x

Keywords

Navigation